Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Nanoscale Horiz. 2021 Feb 15;6(4):319–329. doi: 10.1039/d0nh00588f

Figure 4.

Figure 4.

pCCL2 trap facilitates the checkpoint blockade-based therapy. A. Tumor inhibition study of various treatments. Combo trap, the combination of pCCL2 trap and pPD-L1 trap (25 μg pCCL2 combined with 25 μg pPD-L1 on day 7, 10 and 13). *p<0.05, **p<0.01, ***p<0.001. B. Quantitative analysis of tumor weight of various treatment groups on day 26. *p<0.05, **p<0.01, ***p<0.00, ****p<0.0001. C. TUNEL assay and corresponding quantitative analysis of tumor tissue from various treatment groups. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. Tumors were obtained on day 26. **p<0.01, ***p<0.001, ****p<0.0001.